Analysts Set $36.08 Price Target for Catalyst Biosciences Inc (CBIO)

Catalyst Biosciences Inc (NASDAQ:CBIO) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $36.08 for the company and are predicting that the company will post ($1.79) EPS for the current quarter, according to Zacks. Zacks has also assigned Catalyst Biosciences an industry rank of 193 out of 265 based on the ratings given to its competitors.

CBIO has been the topic of a number of research analyst reports. Zacks Investment Research raised Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday, November 8th. B. Riley initiated coverage on Catalyst Biosciences in a report on Friday, December 8th. They set a “buy” rating and a $19.00 target price on the stock. ValuEngine raised Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Chardan Capital increased their target price on Catalyst Biosciences from $10.00 to $75.00 and gave the stock a “buy” rating in a report on Friday.

Shares of Catalyst Biosciences (NASDAQ CBIO) traded up $4.87 on Friday, reaching $32.15. The company had a trading volume of 2,085,995 shares, compared to its average volume of 452,726. The stock has a market capitalization of $158.60, a P/E ratio of -2.45 and a beta of 2.68. Catalyst Biosciences has a 1 year low of $3.11 and a 1 year high of $33.81.

Large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP bought a new position in Catalyst Biosciences during the 2nd quarter worth approximately $372,000. Bank of New York Mellon Corp bought a new position in Catalyst Biosciences during the 2nd quarter worth approximately $107,000. Virtu KCG Holdings LLC bought a new position in Catalyst Biosciences during the 2nd quarter worth approximately $103,000. Finally, Vanguard Group Inc. lifted its holdings in Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after buying an additional 32,621 shares during the last quarter. 22.89% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply